In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.
By Adam Feuerstein
May 7, 2026
Senior Writer, Biotech
Adam Feuerstein
adam.feuerstein@statnews.com
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
NYT: A new drug for a subset of patients 'tells us that ALS is treatable', expert says.
